远程医疗公司Hims & Hers Health Inc.(HIMS.us)于2024年10月30日盘中股价大跌16.06%,引发市场关注。 根据分析师看法,这很可能与该公司减肥药业务所面临的竞争加剧有关。
10月30日,诺和诺德公司的减肥药Wegovy在美国获准上市所有五种剂量强度。这一竞品进入市场或引发了投资者对Hims & Hers Health在减肥药领域业务前景的担忧。
分析机构Leerink Partners指出,尽管GLP-1类似减肥药营收目前在公司总收入中仍占比很小,但HIMS的股价波动可能会受到相关新闻的影响。这种风险可能导致股价经历不必要的大起大落。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments